Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study

Ohkoshi, Akira; Ishii, Ryo; Wakamori, Shun; Nakayama, Yuki; Yoshida, Takuya; Higashi, Kenjiro; Nakanome, Ayako; Ogawa, Takenori; Katori, Yukio

doi:10.1016/j.oraloncology.2021.105475

Cited by 8 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a Japanese study revealed that serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Selenium deficiency before treatment was independently associated with poor compliance with cisplatin ( 19 ). Collectively, these studies support our findings that selenium supplementation ameliorates the toxic effects of chemoradiotherapy without extra gastrointestinal side effects, providing a new strategy to improve the tolerance and compliance of patients to chemoradiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial

Yang

Peng

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

ObjectiveSelenium (Se) is an essential trace element and may affect cervical cancer occurrence and progression. The association between selenium supplementation and acute toxic reactions and clinical outcomes in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy remains unclear. The aim of this study was to determine the safety profile of add-on Se yeast and assess the potential of Se to ameliorate the hematologic toxicity of concurrent chemoradiotherapy in patients with cervical cancer.MethodsPatients with Federation International of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer who met all inclusion criteria were randomly assigned to either the experimental group or the control group. The experimental group received Se yeast tablets (100 μg Se, twice daily), while the control group received placebos (twice daily) for 5 weeks in total. All patients in both groups received standard treatment, including pelvic external irradiation, concurrent five cycles of chemotherapy, and brachytherapy. Measures included the incidence of myelosuppression, impairment of liver and kidney function, objective response rate (ORR), and blood Se concentrations before, during and after the treatment of the two groups.ResultsA total of 104 eligible patients were enrolled in the experimental group (n = 50) or the control group (n = 54). The ORR in the experimental group and control group were 96 and 94%, respectively (p = 0.47). The baseline levels of blood Se before treatment in the experimental and control groups were similar (58.34 ± 17.63 μg/L and 60.21 ± 18.42 μg/L, p = 0.60), but the concentrations became significantly different after course completion between the two groups (76.16 ± 24.47 μg/L and 57.48 ± 14.92 μg/L, respectively, p < 0.01). Se dramatically decreased the incidence of grade 3 myelosuppression (48% vs. 63%, p = 0.034) compared to the control group. In the subgroup of patients with moderately well-differentiated cervical cancer, the incidence of thrombocytopenia induced by concurrent chemoradiotherapy was lower in the experimental group than in the control group (53.8% vs. 78.9%, p < 0.01). However, no difference was observed in liver and kidney injuries between the two groups.ConclusionSupplementation with Se effectively increased blood Se levels in Se-inadequate cervical cancer patients. As an add-on to standard treatment, Se-yeast significantly decreased the hematologic toxicity of concurrent chemoradiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial

Yang

Peng

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…However, reflecting the most aged society in the world, now half of the patients with head and neck cancer are over 70 years old in Japan [ 1 ]. Thus, a considerable number of elderly patients with head and neck cancers are not feasible for CRT due to the decreased functions of these organs [ 21 ], as shown in the present study. The larger proportion of elderly patients with HPC might be the most possible reason why more patients with HPC have been surgically treated in Japan.…”

Section: Discussionmentioning

confidence: 94%

Oncological Outcomes of Concurrent Chemoradiotherapy and Surgical Treatment for Patients With T3 Hypopharyngeal Cancer: A Single-Center Retrospective Analysis

Yui,

Matsuno,

Furukawa

et al. 2024

Cureus

View full text Add to dashboard Cite

“…This result is in agreement with a recent investigation to determine the predictors in compliance with DDP treatment for locally advanced head and neck squamous-cell carcinoma. Selenium deficiency before treatment is an important negative factor for the usage of full-dose cisplatin [ 48 ]. All these are consistent with our results here that the selenium status in diet affected DDP-induced nephrotoxicity.…”

Section: Discussionmentioning

confidence: 99%

Selenium Status in Diet Affects Nephrotoxicity Induced by Cisplatin in Mice

et al. 2022

View full text Add to dashboard Cite

Cisplatin is one of the most active chemotherapy drugs to treat solid tumors. However, it also causes various side effects, especially nephrotoxicity, in which oxidative stress plays critical roles. Our previous studies found that cisplatin selectively inhibited selenoenzyme thioredoxin reductase1 (TrxR1) in the kidney at an early stage and, subsequently, induced the activation of Nrf2. However, the effects of selenium on cisplatin-induced nephrotoxicity are still unclear. In this study, we established mice models with different selenium intake levels to explore the effects of selenoenzyme activity changes on cisplatin-induced nephrotoxicity. Results showed that feeding with a selenium-deficient diet sensitize the mice to cisplatin-induced damage, whereas selenium supplementation increased the activities of selenoenzymes TrxR and glutathione peroxidase (GPx), changed the renal cellular redox environment to a reduced state, and exhibited protective effects. These results demonstrated the correlation of selenoenzymes with cisplatin-induced side effects and provided a basis for the potential approach to alleviate cisplatin-induced renal injury.

show abstract

Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study

Cited by 8 publications

References 34 publications

Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial

Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial

Oncological Outcomes of Concurrent Chemoradiotherapy and Surgical Treatment for Patients With T3 Hypopharyngeal Cancer: A Single-Center Retrospective Analysis

Selenium Status in Diet Affects Nephrotoxicity Induced by Cisplatin in Mice

Contact Info

Product

Resources

About